Celgene Corporation (NASDAQ:CELG) announced this morning that it is acquiring Juno Therapeutics Inc (NASDAQ:JUNO) for $9 billion or $87/share (net of the ~10% it …
In reaction to acquisition buzz in the market’s grapevine, Maxim’s Jason McCarthy is out boosting his price target on Juno stock.
Healthcare analysts share thoughts on a potential acquisition of Juno Therapeutics.
Juno Therapeutics Inc (NASDAQ:JUNO) shares gained 9% after the company said it will present updated clinical and preclinical results from the company and …
In a research report released Friday, FBR analyst Edward White reiterated an Outperform rating on shares of Juno Therapeutics (NASDAQ:JUNO), with a price target …
In a research report released today, Maxim analyst Jason McCarthy reiterated a Buy rating on shares of Juno Therapeutics (NASDAQ:JUNO), with a price target …
Biotech earnings reports often give just as much insight into future plans as they do on past successes. Analysts from FBR & Co.
Juno Therapeutics Inc (NASDAQ:JUNO), a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, today reported business highlights …
Juno Therapeutics Inc (NASDAQ:JUNO), a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, announced the U.S.
Juno Therapeutics Inc (NASDAQ:JUNO), a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, announced that it has …
